Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer

Artioli Grazia, Mocellin Simone, Borgato Lucia, Cappetta Alessandro, Bozza Fernando, Zavagno Giorgio, Zovato Stefania, Marchet Alberto, Pastorelli Davide

Research output: Contribution to journalArticle

Abstract

Aim: This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-advanced breast cancer. Patients and Methods: Fifty patients with histological confirmation of locally advanced breast cancer received treatment with gemcitabine 1000 mg/m2 (day 1) followed by gemcitabine 800 mg/m2 plus docetaxel 75 mg/m2 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 (day 8) every 3 weeks for at least 4 cycles, plus a final 2 additional cycles. Tumour size was Tl (n=2), T2 (n=32), T3 (n=14), T4 (n=2). All 50 patients underwent surgery. Results: Clinical complete, partial and no response were observed in 13 (26%), 24 (48%) and 11 (22%) patients, respectively (overall response rate: 74%). The number of chemotherapy cycles was found to be an independent predictor of a pathologic complete response. Conclusion: The combination of gemcitabine-docetaxel-PLD can yield high tumour response rates in patients with locally-advanced breast cancer who undergo a full treatment of 6 cycles.

Original languageEnglish
Pages (from-to)3817-3821
Number of pages5
JournalAnticancer Research
Volume30
Issue number9
Publication statusPublished - 2010

Keywords

  • Breast cancer
  • Chemotherapy
  • Docetaxel
  • Gemcitabine
  • Locally advanced
  • Neoadjuvant
  • Pegylated liposomal doxorubicin
  • Phase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Grazia, A., Simone, M., Lucia, B., Alessandro, C., Fernando, B., Giorgio, Z., Stefania, Z., Alberto, M., & Davide, P. (2010). Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Research, 30(9), 3817-3821.